HM Medical Clinic


Acon *hcg

Ora-Check Complete 6 Drug Screen Device Using an immunoassay cutoff level of 40 ng/mL, codeine can be detected in the oral fluid within 1 hour following a single oral dose and can remain detectable for 7-21 hours after the dose2. Heroin metabolite Package Insert for the AMP/MET/COC/OPI/THC/BZO Materials Provided 6-monoacetylmorphine (6-MAM) is found more prevalently in excreted unmetabolized, and is also the • Test devices • Package insert Test for Oral Fluids major metabolic product of codeine and heroin. A rapid, screening test for the simultaneous, qualitative detection of amphetamine, methamphetamine, cocaine, opiates, THC ,BZO and their metabolites in human oral fluid. For Forensic Use Only The opiates assay contained within the Oral Fluid Drug Screen Device yields a positive result when the DIRECTIONS FOR USE opiates concentration in oral fluid exceeds 40 ng/mL. Allow the test device, specimen, and/or controls to reach room temperature (15-30°C) prior to testing. Instruct the donor to not place anything in the mouth including food, drink, gum or tobacco products for at least 10 minutes prior to collection. The Oral Fluid Drug Screen Device for AMP/MET/COC/OPI/THC/BZO is a lateral flow chromatographic Tetrahydrocannabinol (THC), the active ingredient in the marijuana plant (cannabis sativa), is detectable 1. Specimen Collection immunoassay for the qualitative detection of amphetamine, methamphetamine, cocaine, opiates, THC, in oral fluid shortly after use. The detection of the drug is thought to be primarily due to the direct 2. Using the provided oral fluid swab, sweep the inside of the mouth for 3 minutes. The sponge will BZO and their metabolites in oral fluids at the following cut-off concentrations: exposure of the drug to the mouth (oral and smoking administrations) and the subsequent sequestering gradually soften as oral fluid is absorbed, and should be completely saturated after 3 minutes. of the drug in the buccal cavity.3 Historical studies have shown a window of detection for THC in oral fluid 3. Test Procedure of up to 14 hours after drug use.3 4. Remove the test from its sealed pouch, and place it on a clean, level surface. Label the test with Amphetamine (MAMP) patient or control identification. For best results, the assay should be performed within one hour. The THC assay contained within the Oral Fluid Drug Screen Device yields a positive result when the Methamphetamine (MET) d-Methamphetamine Insert the moistened swab firmly into the collection chamber. Press down firmly to release as much Δ9-THC concentration in oral fluid exceeds 50 ng/mL. liquid as possible. 6. Avoid trapping air bubbles in the specimen wells (S), and do not add any solution to the result areas. Benzodiazepine (BZO) Benzodiazepine (BZO): 7. As the test begins to work, color will migrate across the membrane. Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of 8. Wait for the colored band(s) to appear. The result should be read at 5-10 minutes. Do not interpret anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical the result after 20 minutes. called gamma aminobutyric acid (GABA). Because they are safer and more effective, Benzodiazepines This assay provides only a preliminary analytical test result. A more specific alternate chemical have replaced Barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass used as sedatives before some surgical and medical procedures, and for the treatment of seizure spectrometry (GC/MS) and gas chromatography/tandem mass spectrometry (GC/MS/MS) are the disorders and alcohol withdrawal. preferred confirmatory methods. Professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated. The Oral Fluid Drug Screen Device for AMP/MET/COC/OPI/THC/BZO is an immunoassay based on the The Oral Fluid Drug Screen Device for AMP/MET/COC/OPI/THC/BZO and their metabolites is a rapid, oral principle of competitive binding. Drugs that may be present in the oral fluid specimen compete against fluid screening test that can be performed without the use of an instrument. The test utilizes monoclonal their respective drug conjugate for binding sites on their specific antibody. antibodies to selectively detect elevated levels of specific drugs in human oral fluid. During testing, a portion of the oral fluid specimen migrates upward by capillary action. A drug, if Amphetamine (AMP) present in the oral fluid specimen below its cut-off concentration, will not saturate the binding sites of its INTERPRETATION OF RESULTS specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line Amphetamine is a sympathomimetic amine with therapeutic indications. The drug is often self- will show up in the test line region of the specific drug strip. The presence of drug above the cut-off (Please refer to the previous illustration) administered by nasal inhalation or oral ingestion. Depending on the route of administration, concentration in the oral fluid specimen will saturate all the binding sites of the antibody. Therefore, the NEGATIVE:* Two lines appear. One colored line should be in the control region (C), and another amphetamine can be detected in oral fluid as early as 5-10 minutes following use1. Amphetamine can colored line will not form in the test line region. apparent colored line adjacent should be in the test region (Drug/T). This negative result indicates that be detected in oral fluids for up to 72 hours after use1. the drug concentration is below the detectable level. A drug-positive oral fluid specimen will not generate a colored line in the specific test line region of the *NOTE: The shade of color in the test line region (Drug/T) will vary, but it should be considered negative The amphetamine assay contained within the Oral Fluid Drug Screen Device yields a positive result when strip because of drug competition, while a drug-negative oral fluid specimen will generate a line in the whenever there is even a faint line. the amphetamine concentration in oral fluid exceeds 50 ng/mL. test line region because of the absence of drug competition. Methamphetamine (MAMP) To serve as a procedural control, a colored line will always appear at the control line region, indicating POSITIVE: One colored line appears in the control region (C). No line appears in the test region that proper volume of specimen has been added and membrane wicking has occurred. (Drug/T). This positive result indicates that the drug concentration is above the detectable level. Methamphetamine is a potent stimulant chemically related to amphetamine but with greater CNS INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques stimulation properties. The drug is often self-administered by nasal inhalation, smoking or oral are the most likely reasons for control line failure. Review the procedure and repeat the test using a new ingestion. Depending on the route of administration, methamphetamine can be detected in oral fluid as The test contains membrane strips coated with drug-protein conjugates (purified bovine albumin) on the test panel. If the problem persists, discontinue using the lot immediately and contact the manufacturer. early as 5-10 minutes following use1. Methamphetamine can be detected in oral fluids for up to 72 test line, a goat polyclonal antibody against gold-protein conjugate at the control line, and a dye pad hours after use1. which contains colloidal gold particles coated with mouse monoclonal antibody specific to Amphetamine, Methamphetamine, Benzoylecgonine, Morphine, Δ9- THC and BZO. A procedural control is included in the test. A colored line appearing in the control region (C) is The Methamphetamine assay contained within the Oral Fluid Drug Screen Device yields a positive result considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane when the methamphetamine concentration in oral fluid exceeds 50 ng/mL. wicking and correct procedural technique. • For forensic use only. • Do not use after the expiration date. Cocaine is a potent central nervous system (CNS) stimulant and a local anesthetic derived from the coca • The Oral Fluid test device should remain in the sealed pouch until use. 1. The Oral Fluid Drug Screen Device provides only a qualitative, preliminary analytical result. A plant (erythroxylum coca). The drug is often self-administered by nasal inhalation, intravenous injection • Saliva is not classified as biological hazard unless derived from a dental procedure. secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass and free-base smoking. Depending on the route of administration, cocaine and metabolites • The used collector and device should be discarded according to federal, state and local regulations. spectrometry (GC/MS) or gas chromatography/tandem mass spectrometry (GC/MS/MS) is preferred benzoylecgonine and ecgonine methyl ester can be detected in oral fluid as early as 5-10 minutes confirmatory methods. following use1. Cocaine and benzoylecgonine can be detected in oral fluids for up to 24 hours after use1. STORAGE AND STABILITY 2. A positive test result does not indicate the concentration of drug in the specimen or the route of Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed The cocaine assay contained within the Oral Fluid Drug Screen Device for cocaine and opiates yields a on the sealed pouch. The test devices must remain in the sealed pouch until use. DO NOT FREEZE. Do 3. A negative result may not necessarily indicate a drug-free specimen. Drug may be present in the positive result when the cocaine metabolite in oral fluid exceeds 20 ng/mL. not use beyond the expiration date. specimen below the cutoff level of the assay. SPECIMEN COLLECTION AND PREPARATION The drug class opiates refers to any drug that is derived from the opium poppy, including naturally The oral fluid specimen should be collected using the collector provided with the kit. Follow the detailed occurring compounds such as morphine and codeine and semi-synthetic drugs such as heroin. Opiates Directions for Use below. No other collection devices should be used with this assay. Oral fluid collected act to control pain by depressing the central nervous system. The drugs demonstrate addictive at any time of the day may be used. properties when used for sustained periods of time; symptoms of withdrawal may include sweating, shaking, nausea and irritability. Opiates can be taken orally or by injection routes including intravenous, intramuscular and subcutaneous; illegal users may also take the intravenously or by nasal inhalation.

o-Hydroxyhippuric acid PERFORMANCE CHARACTERISTICS p-Hydroxytyramine d/l-Isoproterenol Analytical Sensitivity A Phosphate-buffered saline (PBS) pool was spiked with drugs to target concentrations of ± 50% cut-off and ± 25% cut-off and tested with the Oral Fluid Drug Screen Device. The results are summarized below. Morphine 3-β-D-Glucuronide d-Norpropoxyphene Pentazocine hydrochloride Diacetylmorphine (Heroin) 6-Monoacetylmorphine Trans-2-phenylcyclopropylamine hydrochloride Phenylpropanolamine Benzodiazepine (BZO) d-Pseudoephedrine Chlordiazepoxide Tetrahydrocortisone 3-acetate Tetrahydrocortisone 3 (β-D-glucuronide) Desalkyflurazepam Analytical Specificity The following table lists the concentration of compounds (ng/mL) above which the Oral Fluid Drug Screen device for AMP/MET/COC/OPI/THC/PCP identified positive results at a read time of 10 minutes. 1. Moolchan, E., et al, "Saliva and Plasma Testing for Drugs of Abuse: Comparison of the Disposition and Pharmacological Effects of Cocaine", Addiction Research Center, IRP, NIDA, NIH, Baltimore, MD. As presented at the SOFT-TIAFT meeting October 1998. 2. Kim, I, et al, "Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration", Clin Chem, 2002 Sept.; 48 (9), pp 1486-96. 3. Schramm, W. et al, "Drugs of Abuse in Saliva: A Review," J Anal Tox, 1992 Jan-Feb; 16 (1), pp 1-9 4. McCarron, MM, et al, "Detection of Phencyclidine Usage by Radioimmunoassay of Saliva," J Anal Tox. Ecgonine methyl ester 1984 Sep-Oct.; 8 (5), pp 197-201. AMPHETAMINE (AMP) Cross-Reactivity A study was conducted to determine the cross-reactivity of the test with compounds spiked into drug- free PBS stock. The following compounds demonstrated no false positive results on the Oral Fluid Drug ß-Phenylethylamine Screen Device when tested with at concentrations up to 100 µg/mL. p-Hydroxyamphetamine (+)3,4-Methylenedioxyamphetamine (MDA) N-Acetylprocainamide Acetylsalicylic acid METHAMPHETAMINE (MET) d-Methamphetamine Andatech Corporation Pty Ltd d/l-Brompheniramine Methoxyphenamine Nunawading VIC 3131 3,4-Methylenedioxymethamphetamine (MDMA) d/l-Chloropheniramine (1R,2S) - (-) Ephedrine MARIJUANA (THC) Deoxycorticosterone Dextromethorphan [email protected] 11-nor-Δ9 - THC -9 COOH Estrone-3-sulfate Ethyl-p-aminobenzoate l(–)-Epinephrine Hydrochlorothiazide


Anticonvulsant activity of bisabolene sesquiterpenoids of curcuma longa in zebrafish and mouse seizure models

Contents lists available at Epilepsy & Behavior Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models Adriana Monserrath Orellana-Paucar , Ann-Sophie K. Serruys Tatiana Afrikanova , Jan Maes ,Wim De Borggraeve Jo Alen Fabián León-Tamariz Isabel María Wilches-Arizábala ,Alexander D. Crawford Peter A.M. de Witte , Camila V. Esguerra a Laboratory for Molecular Biodiscovery, Department of Pharmaceutical & Pharmacological Sciences, University of Leuven, Leuven, Belgiumb Escuela de Bioquímica y Farmacia, Facultad de Ciencias Químicas, Universidad de Cuenca, Cuenca, Ecuadorc Molecular Design and Synthesis, Department of Chemistry, University of Leuven, Leuven, Belgium

Imageprogrf_ipf 770/670

iPF670 shown with stand Designed for low-volume printing, these printers offer affordable AVAILABLE WORKFLOW SOLUTIONS solutions that can support a variety • Mobile printing app*• Direct Print & Share** of applications including: posters, • PosterArtist Lite presentations, technical documents, • Print Plug-in for Microsoft Office®, and more!